{"id":"W4226263934","doi":"10.2337/dc21-2034","title":"Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials","year":2022,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"National Center for Advancing Translational Sciences; National Heart, Lung, and Blood Institute; Sanofi Genzyme; Centers for Disease Control and Prevention; National Institutes of Health; Eli Lilly and Company; Ono Pharmaceutical; Chugai Pharmaceutical; Akebia Therapeutics; Mitsubishi Tanabe Pharma Corporation; Relypsa; Astellas Pharma; Novo Nordisk; Nipro; Kidney Foundation of Canada; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; Kowa Company; U.S. Department of Veterans Affairs; Alexion Pharmaceuticals; Daiichi Sankyo Europe; Gilead Sciences; Heart and Stroke Foundation of Canada; Kissei; AstraZeneca; GlaxoSmithKline; Amgen","keywords":"Empagliflozin; Medicine; Placebo; Internal medicine; Kidney disease; Discontinuation; Diabetes mellitus; Type 2 diabetes; Hazard ratio; Proportional hazards model; Clinical trial; Adverse effect; Randomized controlled trial; Surgery; Confidence interval; Endocrinology; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0552315,0.002584284,0.0151792,0.003634103,0.0003110316,0.003123959,0.001085852,0.002168171,0.001843134],"category_scores_gemma":[0.07725024,0.001230764,0.02630377,0.003712683,0.0007557918,0.001658225,0.001410759,0.001373318,0.0002061483],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000734168,"about_ca_system_score_gemma":0.001075845,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006418427,"about_ca_topic_score_gemma":0.0007365117,"domain_scores_codex":[0.9446249,0.03559082,0.01088717,0.004196291,0.004195807,0.0005050144],"domain_scores_gemma":[0.9472362,0.03193859,0.01460106,0.002982999,0.002766153,0.000474975],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.1017878,0.0001343611,0.01566374,0.03120127,0.8185284,0.00008880203,0.00005615012,0.001335045,0.0007901049,0.0001124826,0.0009700978,0.02933172],"study_design_scores_gemma":[0.06969729,0.007562192,0.04831567,0.003335783,0.8632442,0.0003116991,0.00006481506,0.002228011,0.0008071508,0.0008080474,0.003540684,0.00008444565],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.1490732,0.8220746,0.01434982,0.001073702,0.001516674,0.003386278,0.005818517,0.0003963585,0.002310839],"genre_scores_gemma":[0.880626,0.1005341,0.006453062,0.001307623,0.001354275,0.004182314,0.004855858,0.0001003481,0.0005865192],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.0552315,"threshold_uncertainty_score":0.2920955,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01395502804113343,"score_gpt":0.2923727435065641,"score_spread":0.2784177154654306,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}